Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early access open-label study of ivosidenib in pretreated advanced cholangiocarcinoma
2022-501463-40-01Phase 3Authorised
- Sponsor
- Servier
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of ivosidenib in cholangiocarcinoma (CCA), sponsored by Servier. Primary endpoint: Safety and tolerability. Planned start Apr 2023; status: authorised.
02
Drugs
ivosidenib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2022-501463-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501463-40-01.